The use of Allergoids and Adjuvants in Allergen Immunotherapy

Olivier, Celso Eduardo

doi:10.29328/journal.haard.1001006

Cited by 12 publications

(10 citation statements)

References 203 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Будущие перспективы АСИТ включают разработку альтернативных способов введения аллергенов, иммуномодулирующих адъювантов, аллергоидов [29,30], рекомбинантных вакцин [18,[31][32][33], контейнеров для аллергенов типа вирусоподобных частиц и липосом. Главная цель усовершенствования АСИТ заключается в укорочении существующих протоколов без потери эффективности иммунотерапии, создании лучшего профиля побочных реакций и распространение АСИТ в развивающихся странах [3].…”

Section: __________________________unclassified

Allergen-specific immunotherapy in allergic rhinitis

et al. 2022

View full text Add to dashboard Cite

The review focuses on allergen-specific immunotherapy (AIT), a treatment method for atopic diseases, including allergic rhinitis. The theoretical and practical basics, development prospects, indications and contraindications to AIT, peculiarities of AIT execution in allergic rhinitis, and tolerogenic effects of immunotherapy are considered. Advantages and disadvantages of each of the two preferable routes of allergen administration in AIT, subcutaneous and sublingual, are described. The main goals of further AIT advancement include shortening of treatment protocols with no significant loss of efficacy, creation of a safer adverse effect profile, and distribution of AIT in developing countries.

show abstract

Section: __________________________unclassified

Allergen-specific immunotherapy in allergic rhinitis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Allergoids are modified allergen extracts whose allergenicity has been reduced with preserved immunogenic activity [ 36 ]. Allergoids are commonly administered subcutaneously; however, Martinez et al [ 37 ] conducted the first randomized controlled trial (RCT) in IDIT using P. pratense allergoid with a satisfactory result.…”

Section: Modified Formulations Of Intradermal Immunotherapymentioning

confidence: 99%

Intradermal Allergen Immunotherapy for Allergic Rhinitis: Current Evidence

Atipas

Kanjanawasee

Tantilipikorn

2022

JPM

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated inflammatory disease that is induced by allergen introduction to the nasal mucosa, which triggers an inflammatory response. The current treatments for AR include allergen avoidance and pharmacotherapy; however, allergen-specific immunotherapy (AIT) is the only treatment that can be employed to modify immunologic responses and to achieve a cure for allergic diseases. The current standard routes of AIT administration are the subcutaneous and sublingual routes. Alternatively, the dermis contains a high density of dermal dendritic cells that act as antigen-presenting cells, so intradermal administration may confer added advantages and increase the efficacy of AIT. Moreover, intradermal immunotherapy (IDIT) may facilitate a reduction in the allergen dosage and a shortening of the treatment duration. The aim of this review was to search and evaluate the current evidence specific to IDIT, including its modified formulations, such as allergoids and peptides. The results of this review reveal conflicting evidence that suggests that the overall benefit of IDIT remains unclear. As such, further clinical trials are needed to establish the clinical utility of IDIT, and to determine the optimal treatment-related protocols.

show abstract

“…The great variety of allergens of the Hb latex and the diversity of hypersensitivity reactions and crossreactions turn the allergy to natural latex proteins into a complex immune condition requiring a multi-parametric approach [10]. The main strategy to treat these latex-fruitpollen syndromes is avoidance and sublingual desensitization, a practice first described in 1901 with natural pollens and nowadays with their allergoids [16]- [24]. The diagnosis of the Gell and Coombs' type I IgE-mediated hypersensitivity is a relatively easy task done with the help of allergic skin tests or immunoassays designed to detect latexspecific IgE.…”

Section: Introductionmentioning

confidence: 99%

Contribution of the Leukocyte Adherence Inhibition Test to the Evaluation of Cellular Immunoreactivity against Latex Extracts for Non—IgE-Mediated Latex-Fruit-Pollen Syndrome in Allergic Candidates to Exclusion Diets and Allergic Desensitization

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Due to the lack of standardized laboratory procedures able to demonstrate specific non—IgE-mediated immune responses against latex allergens, these conditions are diagnosed mostly by clinical criteria based on empiric exclusion prescriptions monitored by in vivo challenge tests. Objective: To evaluate the opportunity of an ex vivo challenge immunoassay, the Leukocyte Adherence Inhibition (LAI) Test (LAIT), to discriminate non—IgE-mediated latex-specific immunoreactivity. Methods: Ex vivo challenge tests performed with Hevea Brasiliense’s latex extract, monitored by LAIT, were assayed in an asymptomatic control group and a group of patients with diverse respiratory and cutaneous non—IgE-mediated allergic conditions, clinically diagnosed by a certified allergologist. Results: The mean LAI of the control group was 8.3%. The mean LAI of the complete patients’ group was 41.1%. The non-parametric Wilcoxon-Mann-Whitney U (WMWU) test comparing the control group with the whole patient’s group showed significance with a p-value < 0.00001. The WMWU test comparing the control group with each other patient’s group showed significance with a p-value < α = 0.05 for all comparisons. The WMWU test comparing the patients’ groups between each other did not show any significant p-value. Conclusion: Several patients from the diverse non—IgE-mediated allergic phenotypes presented variable immunoreactivity against the latex extract, as demonstrated by the LAIT, which proved to be an easy, quick, and inexpensive ex vivo immunoassay with the potential to predict individual immunoreactivity against Hevea brasiliensis latex allergens in real-world patients with non—IgE-mediated allergies.

show abstract

The use of Allergoids and Adjuvants in Allergen Immunotherapy

Cited by 12 publications

References 203 publications

Allergen-specific immunotherapy in allergic rhinitis

Allergen-specific immunotherapy in allergic rhinitis

Intradermal Allergen Immunotherapy for Allergic Rhinitis: Current Evidence

Contribution of the Leukocyte Adherence Inhibition Test to the Evaluation of Cellular Immunoreactivity against Latex Extracts for Non—IgE-Mediated Latex-Fruit-Pollen Syndrome in Allergic Candidates to Exclusion Diets and Allergic Desensitization

Contact Info

Product

Resources

About